Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Niraparib in High-grade Endometrial Cancer
NCT05289648Phase 1Withdrawn
- Sponsor
- Jewish General Hospital
- Start
- May 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of niraparib in endometrial cancer (EC), sponsored by Jewish General Hospital. Primary endpoints: Tumor cells proliferation before and after the treatment at Day 30, Cell cycle arrest at Day 30 and 1 more. Planned start May 2024; status: withdrawn.
02
Drugs
niraparib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05289648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05289648.